Crinetics Pharmaceuticals, Inc.
CRNX
Rankning i aktier
#2230
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aktiekurs
$84.95
Senast synkroniserad: 2026-09-01
Marknadsvärde
$9.00B
Förändring (1 dag)
0.00%
Förändring (1 år)
98.25%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
P/B-tal för Crinetics Pharmaceuticals, Inc. (CRNX)
P/B-tal per October 2026 TTM: 7.52
Enligt Crinetics Pharmaceuticals, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 7.52. I slutet av 2023 hade företaget ett P/B-tal på 3.83.
Historik för P/B-tal för Crinetics Pharmaceuticals, Inc. från 2016 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 7.52 | 141.13% |
| 2024 | 3.12 | -18.65% |
| 2023 | 3.83 | 27.45% |
| 2022 | 3.01 | -8.58% |
| 2021 | 3.29 | 29.34% |
| 2020 | 2.54 | -139.33% |
| 2019 | -6.47 | -22.97% |
| 2018 | -8.39 | -62.93% |
| 2017 | -22.64 | -58.70% |
| 2016 | -54.83 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -16.91% |
US
|
|
| 13.2547 | 76.18% |
US
|
|
| 4.208 | -44.07% |
AU
|
|
| 6.1824 | -17.82% |
NL
|
|
| - | - |
CH
|
